What Is Aripiprazole?
7- {4- [4- (2,3-dichlorophenyl) -l-piperazinyl] butoxy} -3,4-dihydro-2 (1H) -quinolinone
- Aripiprazole is used to treat all types of schizophrenia. Foreign clinical trials have shown that this product has obvious effects on both the positive and negative symptoms of schizophrenia, and can also improve the associated emotional symptoms and reduce the recurrence rate of schizophrenia.
- Drug name
- Aripiprazole
- Drug type
- Essential medicines
- English name
- Aripiprazole
- Chinese alias
- Abilice; Bosqing; Herning
- English alias
- Brisking; Abilify
Aripiprazole chemical name
- 7- {4- [4- (2,3-dichlorophenyl) -l-piperazinyl] butoxy} -3,4-dihydro-2 (1H) -quinolinone
Aripiprazole molecular structure
Aripiprazole molecular formula
- C23H27N302Cl2
Aripiprazole molecular weight
- 448
Aripiprazole physical and chemical properties
- Colorless crystalline powder.
Aripiprazole Pharmacology
- This product is a new type of atypical anti-schizophrenia drug. It has a two-way regulating effect on the DA energy nervous system and is a stabilizer of DA transmitters. Has high affinity for D2, D3, 5-HT1A and 5-HT2A receptors. The anti-schizophrenic effect is produced by partial agonism of D2 and 5-HT1A receptors and antagonism of 5-HT2A receptors. The peak time of blood concentration of this product after oral administration is 3 ~ 5 hours, and the half-life is 48 ~ 68 hours. Dehydroaripiprazole is the main active metabolite.
Aripiprazole indications
- It is used to treat various types of schizophrenia. Foreign clinical trials have shown that this product has obvious effects on both the positive and negative symptoms of schizophrenia, and can also improve the associated emotional symptoms and reduce the recurrence rate of schizophrenia.
Aripiprazole usage and dosage
- Due to different dosage forms and specifications, please read the drug instructions carefully or follow the doctor's advice.
Aripiprazole adverse reactions
- It is relatively light and has a low incidence of weight gain and extrapyramidal reactions, so the patient is better tolerated. The main adverse reactions were headache, anxiety, insomnia, drowsiness, urinary incontinence, and sitting still.
Aripiprazole contraindications
- Those who are allergic to this medicine are prohibited.
Aripiprazole precautions
- Be cautiously used in patients with cardiovascular disease (history of myocardial infarction, ischemic heart disease, heart failure or conduction abnormalities), patients with cerebrovascular disease or conditions that induce hypotension (such as dehydration, hypovolemia, and antihypertensive drugs) ). Be used with caution in cases with a history of epilepsy or a low epilepsy threshold. Be used with caution in patients at risk for aspiration pneumonia.
Aripiprazole preparation
- Tablets, capsules, orally disintegrating tablets: 5mg, 10mg
Aripiprazole Pharmacopeia Introduction
- [Identification] (1) Take an appropriate amount of this product, add methanol to make a solution containing about 16µg per lml, and measure it by ultraviolet-visible spectrophotometry (Chinese Pharmacopoeia 2005 Edition Two Appendix IV A). absorb. (2) According to the chromatographic condition test under the relevant substance, take an appropriate amount of aripiprazole reference substance, add mobile phase ultrasonic treatment for 10 minutes to dissolve, and dilute to a solution containing about 0.25 mg per 1 ml. 20 l each of the reference solution and the test solution under the relevant substance were injected into the liquid chromatograph, and the chromatogram was recorded. The retention time of the main peak of the test solution should be consistent with that of the main solution of the reference solution. (3) The infrared absorption spectrum of this product should be the same as that of the reference substance (Chinese Pharmacopoeia 2005 Edition Appendix IV C). (4) Take an appropriate amount of this product and inspect it by X-ray powder diffraction method (Appendix F of the second part of the Chinese Pharmacopoeia 2005 Edition). There should be characteristic diffraction peaks at 1Å, 4. 6Å ± 0.1Å, 4. 4Å ± 0.lÅ, and 4. 0Å ± 0.1Å. [Inspection] Take this product, add mobile phase sonication for 10 minutes to dissolve and dilute it to a solution containing about 0.25mg per 1ml as the test solution; take a precise amount of 1.0ml of the test solution and set it to 100ml In the bottle, add the mobile phase and dilute to the mark. As a control solution, determine by high performance liquid chromatography (Chinese Pharmacopoeia 2005 Version Two Appendix VD). Use octylsilane-bonded silica gel as a filler. Acetonitrile-0.03m0l / L ammonium acetate solution-triethylamine (60: 40: 0.2) is the mobile phase; the detection wavelength is 254nm. The theoretical plate number is calculated to be not less than 4000 based on the aripiprazole peak. Measure 20µl of the control solution and inject it into the liquid chromatograph. Adjust the detection sensitivity so that the peak height of the main component chromatographic peak is about 20% of the full scale. Precisely measure 20µ1 each of the test solution and the reference solution and immediately inject them into the liquid chromatograph respectively. Record the chromatogram to 2.5 times the peak retention time of the main component. The sum of the values must not be greater than the area of the main peak of the control solution. Residual solvents shall be inspected according to the method for determination of residual solvents (Appendix P of the Second Part of the Chinese Pharmacopoeia 2005 Edition) and shall comply with the regulations. Loss on drying: Take this product and dry it at 105 to constant weight. The weight loss should not exceed 0.5% (Chinese Pharmacopoeia 2005 Edition Appendix L) Take 1.0g of this product and check it according to law (Appendix N of the second part of the Chinese Pharmacopoeia 2005 Edition). The residue should not exceed 0.1%. The heavy metal is taken from the residue under the burning residue and inspected in accordance with the law (the second method of Appendix VI H of the Chinese Pharmacopoeia 2005 Edition), and the heavy metal must not exceed 10 parts per million. [Content determination] Take about 0.35g of this product, accurately weigh, add 30ml of glacial acetic acid to dissolve, add 1 drop of crystal violet indicator solution, titrate with perchloric acid titrant (0.1mol / L), and titrate until the solution is blue Color, and the results of the titration are corrected with a blank test. Each 1ml of perchloric acid titration solution (0.1mol / L) is equivalent to 44.84mg of C23H27N302C12. [Category] Antipsychotics. [Storage] shading and sealed.